Bladder cancer is one of the most common forms of urological cancer, and early detection can mean the difference between effective treatment and advanced disease. Today, thanks to innovative technologies, it is possible to detect the tumor more accurately and quickly. Prominent among these advanced diagnostic tools is FISH (Fluorescence In Situ Hybridization), a molecular technique increasingly used for the early detection of bladder cancer.

FISH is a method that allows the identification of genetic abnormalities directly in the cells found in a patient's urine. Unlike traditional urinary cytology, which is often limited by low sensitivity, FISH detects chromosomal alterations characteristic of bladder tumors, even at an early stage.

This examination is recommended in various contexts:

- For patients with suspected bladder cancer but negative cytology.
- In cases of recurrence in patients already treated for bladder cancer.
- As diagnostic support in patients at risk, such as smokers or people exposed to carcinogens.

- Greater sensitivity than urinary cytology.
- Noninvasive: performed on a simple urine sample.
- Early detection: detects tumor even before it is visible on cystoscopy.
- Also useful for postoperative monitoring or during follow-up.

Early diagnosis is the key to improving patients' prognosis and quality of life. FISH, because of its accuracy, is revolutionizing the way we approach the diagnosis of bladder cancer, integrating seamlessly with other diagnostic tools such as cystoscopy and cytology.

Urinary tract cancers may be silent, but technology now offers us increasingly effective weapons to anticipate them. This technique fits among them, representing a valuable ally for physicians and patients in the fight against urologic cancer.